通往移植的漫长曲折之路:肌肉减少症与衰弱如何影响等待名单上的发病率与死亡率
衰弱与肌肉减少症是肝硬化的常见并发症;二者存在均与发病率及死亡率升高相关,且与失代偿和并发症发生率增加紧密相连。识别这些情况至关重要;研究显示改善肌肉力量与功能可降低死亡率,提示衰弱与肌肉减少症均为可改变的危险因素。本综述概述肝硬化中衰弱与肌肉减少症的患病率及其对失代偿、住院和死亡率等临床结局的影响,并回顾现有及潜在的新型治疗手段。
要点
- 衰弱是生理储备累积下降导致对应激源易感性增加,可源于衰老或疾病过程。
- 肌肉减少症是衰弱的关键组成部分,定义为骨骼肌质量与力量的进行性、全身性丢失。
- 研究显示改善肌肉力量与功能可降低死亡率,提示衰弱与肌肉减少症为可改变的危险因素。
核心结论
- 衰弱与肌肉减少症是肝硬化的常见并发症,二者存在均与发病率及死亡率升高相关。
- 研究显示改善肌肉力量与功能可降低死亡率,提示衰弱与肌肉减少症均为可改变的危险因素。
- 识别衰弱与肌肉减少症至关重要。
研究设计与样本
- 本文为综述,概述肝硬化中衰弱与肌肉减少症的患病率及其对临床结局的影响,并回顾现有与潜在的新型治疗手段。
主要发现
- 衰弱被描述为生理储备累积下降导致对应激源易感性增加,可源于衰老或疾病过程,涉及多个器官系统。
- 肌肉减少症是衰弱的关键组成部分,定义为骨骼肌质量与力量的进行性、全身性丢失。
- 衰弱或肌肉减少症的存在与发病率及死亡率升高相关,并与失代偿和并发症发生率增加紧密相连。
- 研究显示改善肌肉力量与功能可降低死亡率。
局限性
- 原文未报告局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Frailty and sarcopenia are common complications of cirrhosis. Frailty has been described as an increased susceptibility to stressors secondary to a cumulative decline in physiologic reserve; this decline occurs with aging or is a result of the disease process, across multiple organ systems. Sarcopenia, a key component of frailty, is defined as progressive and generalized loss of skeletal muscle mass and strength. The presence of either of these complications is associated with increased morbidity and mortality, as these are tightly linked to decompensation and increased complication rates. Recognition of these entities is critical. Studies have shown improvement in muscle strength and function lead to reduced mortality, suggesting both frailty and sarcopenia are modifiable risk factors. In this review we outline the prevalence of frailty and sarcopenia in cirrhosis and the impact on clinical outcomes such as decompensation, hospitalization, and mortality. Existing and potential novel therapeutic approaches for frailty and sarcopenia are also reviewed.
引用
- Bhanji RA, Carey EJ, Yang L, et al. The Long Winding Road to Transplant: How Sarcopenia and Debility Impact Morbidity and Mortality on the Waitlist. Clin Gastroenterol Hepatol. 2017. PMID: 28400317. doi:10.1016/j.cgh.2017.04.004
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。